Weight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity

Starting soon

Conditions studied: Obesity & Overweight

In brief

SEMAFOLLOW is a real-world follow-up study examining the outcomes of individuals treated with WEGOVY® (semaglutide 2.4 mg) under the temporary authorisation for use (ATU) and early access programme in France. This study evaluates weight change, treatment strategies and well-being, drawing on the expertise of teams from various specialist obesity centres in France.

Key facts

Study ID

NCT07423481

Run by

Nantes University Hospital

People needed

3000

Starts

2026-06-01

Expected to finish

2027-03-01

Last updated by the study team

2026-05-13

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients included in the ATU/early access program for WEGOVY with at least two dispenses of WEGOVY
• No objection to the use of their data
• Patients able to complete an online questionnaire (via the internet)

You may not qualify if…

• Protected patients: minors, adults under guardianship, conservatorship, and/or legal protection

Where it is running

• Nantes university hospital — Nantes, France

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.